Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979251 · ClinicalTrials.gov registry record · Phase 2
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
A Phase 2 study of Influenza, sponsored by Adamas Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 20
- Study locations
NCT00979251 is a Phase 2 study of Influenza that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 2 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00979251, a Phase 2 study of Influenza, has completed, sponsored by Adamas Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.
Conditions Studied
Interventions
- DRUG Oseltamivir Phosphate
- DRUG ADS-8902
Study Locations (20)
California
- Adamas Investigational Site - San Francisco
- Adamas Investigational Site - San Francisco
- Adamas Investigational Site - San Francisco
Florida
- Adamas Investigational Site - Hollywood
- Adamas Investigational Site - Miramar
- Adamas Investigational Site - Pinellas Park
New South Wales
- Adamas Investigational Site - Darlinghurst
- Adamas Investigational Site - Herston
- Adamas Investigational Site - Sydney
Washington
- Adamas Investigational Site - Seattle
- Adamas Investigational Site - Tacoma
Hawaii
- Adamas Investigational Site - Honolulu
Kentucky
- Adamas Investigational Site - Owensboro
Louisiana
- Adamas Investigational Site - New Orleans
Nevada
- Adamas Investigational Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979251
The ClinicalTrials.gov registry entry for NCT00979251 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Adamas Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Oseltamivir Phosphate is the first listed.
NCT00979251 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, New South Wales.
Frequently Asked Questions
What is clinical trial NCT00979251 about?
NCT00979251 is a clinical study titled "Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects". This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric s...
What is the current status of trial NCT00979251?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-09. Estimated completion is 2011-08.
What conditions does trial NCT00979251 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00979251?
The interventions under investigation include: Oseltamivir Phosphate (DRUG), ADS-8902 (DRUG).
Who is sponsoring clinical trial NCT00979251?
This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00979251 being conducted?
This trial has 20 study locations across California, Florida, Hawaii, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.